Nifty
:
9039.25
Sensex
:
30672.59
-67.00 (-0.74%)
-260.31 (-0.84%)
Nifty
Sensex
:
:
9039.25
30672.59
-67.00 (-0.74%)
-260.31 (-0.84%)

Alembic Pharmaceuticals Ltd.

Pharmaceuticals & Drugs - Global

Rating :
88/99

BSE: 533573 | NSE: APLLTD

NSE BSE
898.05
22-May-2020
  • Open
  • High
  • Low
  • Previous Close
  •  900.00
  •  914.40
  •  861.10
  •  897.00
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  808034
  •  7241.14
  •  915.00
  •  434.80

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 16,919.30
  • 20.41
  • 2
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 17,842.11
  • 0.61%
  • 5.25

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 72.97%
  • 0.72%
  • 10.02%
  • FII
  • DII
  • Others
  • 8.29%
  • 6.71%
  • 1.29%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • 13.86
  • 7.87

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • 16.72
  • 6.85

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • 15.99
  • 13.41

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 19.92
  • 21.17
  • 21.26

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 6.07
  • 6.03
  • 4.30

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 14.53
  • 15.39
  • 14.19

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 20
Mar 19
Var%
Dec 19
Dec 18
Var%
Sep 19
Sep 18
Var%
Jun 19
Jun 18
Var%
Net Sales
1,206.83
926.95
30.19%
1,209.13
1,018.15
18.76%
1,240.87
1,127.06
10.10%
948.91
862.53
10.01%
Expenses
879.31
748.91
17.41%
884.07
775.92
13.94%
895.35
824.72
8.56%
723.99
711.54
1.75%
EBITDA
327.52
178.04
83.96%
325.06
242.23
34.19%
345.52
302.34
14.28%
224.92
150.99
48.96%
EBIDTM
27.14%
19.21%
26.88%
23.79%
27.84%
26.83%
23.70%
17.51%
Other Income
0.89
3.37
-73.59%
0.41
3.52
-88.35%
0.36
2.37
-84.81%
3.29
0.10
3,190.00%
Interest
7.75
5.08
52.56%
7.36
5.95
23.70%
7.07
5.81
21.69%
4.98
1.57
217.20%
Depreciation
44.14
29.95
47.38%
41.82
29.05
43.96%
35.95
28.63
25.57%
35.40
27.60
28.26%
PBT
265.66
146.38
81.49%
276.29
210.75
31.10%
302.86
270.27
12.06%
155.04
121.92
27.17%
Tax
62.14
14.90
317.05%
48.60
40.00
21.50%
52.49
70.30
-25.33%
35.96
31.54
14.01%
PAT
203.52
131.48
54.79%
227.69
170.75
33.35%
250.37
199.97
25.20%
119.08
90.38
31.75%
PATM
16.86%
14.18%
18.83%
16.77%
20.18%
17.74%
12.55%
10.48%
EPS
11.92
6.58
81.16%
12.42
9.01
37.85%
13.06
10.61
23.09%
6.56
4.80
36.67%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Net Sales
4,605.74
3,934.68
3,130.18
3,134.61
3,165.99
2,056.13
1,863.22
1,520.35
1,465.41
1,202.05
Net Sales Growth
17.05%
25.70%
-0.14%
-0.99%
53.98%
10.35%
22.55%
3.75%
21.91%
 
Cost Of Goods Sold
1,039.40
992.70
885.56
887.57
823.95
639.85
627.02
609.56
637.39
534.07
Gross Profit
3,566.34
2,941.98
2,244.62
2,247.04
2,342.04
1,416.28
1,236.20
910.78
828.02
667.97
GP Margin
77.43%
74.77%
71.71%
71.68%
73.97%
68.88%
66.35%
59.91%
56.50%
55.57%
Total Expenditure
3,382.72
3,078.58
2,514.92
2,519.90
2,160.88
1,660.92
1,506.16
1,271.75
1,249.54
1,059.04
Power & Fuel Cost
-
88.86
70.35
64.20
58.89
43.31
32.07
26.66
29.57
24.58
% Of Sales
-
2.26%
2.25%
2.05%
1.86%
2.11%
1.72%
1.75%
2.02%
2.04%
Employee Cost
-
746.69
622.81
558.83
472.85
306.76
247.00
193.79
168.46
149.21
% Of Sales
-
18.98%
19.90%
17.83%
14.94%
14.92%
13.26%
12.75%
11.50%
12.41%
Manufacturing Exp.
-
269.25
244.53
289.79
209.91
263.38
272.44
191.95
183.83
145.34
% Of Sales
-
6.84%
7.81%
9.24%
6.63%
12.81%
14.62%
12.63%
12.54%
12.09%
General & Admin Exp.
-
340.56
283.43
299.79
233.28
145.68
117.73
87.73
80.25
63.01
% Of Sales
-
8.66%
9.05%
9.56%
7.37%
7.09%
6.32%
5.77%
5.48%
5.24%
Selling & Distn. Exp.
-
590.04
380.21
393.14
244.62
244.69
194.03
154.78
129.93
113.65
% Of Sales
-
15.00%
12.15%
12.54%
7.73%
11.90%
10.41%
10.18%
8.87%
9.45%
Miscellaneous Exp.
-
50.48
28.03
26.58
117.38
17.26
15.86
7.27
20.11
29.17
% Of Sales
-
1.28%
0.90%
0.85%
3.71%
0.84%
0.85%
0.48%
1.37%
2.43%
EBITDA
1,223.02
856.10
615.26
614.71
1,005.11
395.21
357.06
248.60
215.87
143.01
EBITDA Margin
26.55%
21.76%
19.66%
19.61%
31.75%
19.22%
19.16%
16.35%
14.73%
11.90%
Other Income
4.95
26.86
34.87
2.58
8.83
12.09
4.44
16.71
16.31
21.01
Interest
27.16
18.41
3.40
5.23
5.43
3.81
10.40
23.98
37.55
27.59
Depreciation
157.31
115.23
105.46
82.97
72.21
44.41
40.49
34.97
33.65
29.59
PBT
999.85
749.32
541.27
529.09
936.30
359.07
310.61
206.35
160.98
106.84
Tax
199.19
156.75
120.36
122.19
216.12
76.35
75.10
41.10
30.85
21.46
Tax Rate
19.92%
20.92%
22.24%
23.09%
23.08%
21.26%
24.18%
19.92%
19.16%
20.09%
PAT
800.66
593.65
420.72
406.99
720.18
282.72
235.51
165.25
130.13
85.39
PAT before Minority Interest
828.78
592.57
420.91
406.90
720.18
282.72
235.51
165.25
130.13
85.39
Minority Interest
28.12
1.08
-0.19
0.09
0.00
0.00
0.00
0.00
0.00
0.00
PAT Margin
17.38%
15.09%
13.44%
12.98%
22.75%
13.75%
12.64%
10.87%
8.88%
7.10%
PAT Growth
35.11%
41.10%
3.37%
-43.49%
154.73%
20.05%
42.52%
26.99%
52.39%
 
Unadjusted EPS
43.96
31.00
21.89
21.39
38.19
15.01
12.49
8.77
6.90
4.53

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Shareholder's Funds
2,718.82
2,220.14
1,902.33
1,597.36
884.64
675.57
502.94
395.00
296.73
Share Capital
37.70
37.70
37.70
37.70
37.70
37.70
37.70
37.70
11.00
Total Reserves
2,681.12
2,182.44
1,864.63
1,559.66
846.94
637.87
465.24
357.30
259.03
Non-Current Liabilities
570.08
576.20
94.15
84.02
72.44
94.32
103.25
122.07
150.80
Secured Loans
0.00
0.00
0.00
0.00
18.80
41.95
59.71
76.32
89.67
Unsecured Loans
499.30
500.00
0.00
0.00
0.00
10.27
10.83
18.54
38.81
Long Term Provisions
52.03
40.76
57.22
28.23
9.36
6.68
6.06
5.39
5.10
Current Liabilities
1,489.65
1,144.40
692.67
747.19
684.09
602.51
528.57
583.13
413.28
Trade Payables
702.32
759.32
500.73
565.65
324.94
288.44
239.96
209.15
138.57
Other Current Liabilities
322.20
142.89
81.28
51.80
44.56
60.62
69.25
151.60
84.90
Short Term Borrowings
429.13
207.78
88.51
113.71
219.70
25.42
70.11
138.43
146.28
Short Term Provisions
36.00
34.41
22.15
16.03
94.88
228.02
149.24
83.95
43.53
Total Liabilities
4,777.76
3,941.05
2,689.26
2,428.57
1,641.17
1,372.40
1,134.76
1,100.20
860.81
Net Block
1,158.45
993.38
799.40
708.09
546.87
396.96
344.22
267.82
271.99
Gross Block
1,522.57
1,242.47
950.09
1,093.63
861.06
665.08
572.48
462.91
433.54
Accumulated Depreciation
364.12
249.09
150.69
385.54
314.19
268.12
228.26
195.09
161.55
Non Current Assets
2,820.03
2,116.31
1,316.80
917.30
750.43
515.81
415.66
364.35
308.30
Capital Work in Progress
1,551.23
1,010.15
396.28
92.52
83.14
20.67
32.26
58.24
26.50
Non Current Investment
48.76
41.64
49.88
53.43
2.26
3.36
3.30
3.30
3.26
Long Term Loans & Adv.
61.59
71.14
71.24
29.96
118.15
94.82
35.88
34.99
6.54
Other Non Current Assets
0.00
0.00
0.00
33.30
0.00
0.00
0.00
0.00
0.00
Current Assets
1,957.73
1,824.74
1,372.46
1,511.27
890.74
856.59
719.10
735.85
552.51
Current Investments
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Inventories
967.26
733.93
632.75
569.79
382.77
310.78
266.83
258.74
219.23
Sundry Debtors
488.89
526.34
338.82
350.48
361.17
273.37
232.87
199.33
201.97
Cash & Bank
205.62
89.92
159.60
450.83
26.83
23.96
16.11
47.09
6.29
Other Current Assets
295.96
27.49
7.56
7.09
119.98
248.48
203.29
230.68
125.02
Short Term Loans & Adv.
277.72
447.06
233.73
133.08
119.98
248.48
203.29
230.68
125.02
Net Current Assets
468.08
680.34
679.79
764.08
206.65
254.08
190.53
152.71
139.23
Total Assets
4,777.76
3,941.05
2,689.26
2,428.57
1,641.17
1,372.40
1,134.76
1,100.20
860.81

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Cash From Operating Activity
811.96
312.42
328.55
947.65
171.76
239.97
264.82
141.77
95.00
PBT
749.32
541.27
529.09
936.16
359.07
310.61
206.35
160.98
106.84
Adjustment
120.62
87.12
83.06
69.60
44.61
69.76
53.30
75.09
54.71
Changes in Working Capital
108.52
-180.85
-165.64
138.90
-162.50
-71.53
43.86
-61.59
-48.76
Cash after chg. in Working capital
978.46
447.54
446.51
1,144.66
241.18
308.84
303.51
174.48
112.79
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-166.50
-135.12
-117.96
-197.01
-69.42
-68.87
-38.70
-32.71
-17.80
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-755.60
-884.38
-485.91
-306.80
-255.61
-81.06
-67.02
-56.39
-56.82
Net Fixed Assets
-630.35
-606.86
-121.60
-288.80
-200.26
-81.01
-83.59
-61.11
Net Investments
-215.85
-195.85
-65.58
-4.13
0.00
-29.98
0.00
0.00
Others
90.60
-81.67
-298.73
-13.87
-55.35
29.93
16.57
4.72
Cash from Financing Activity
59.04
502.63
-128.88
-224.30
86.72
-151.06
-228.78
-44.58
-46.95
Net Cash Inflow / Outflow
115.40
-69.33
-286.24
416.55
2.86
7.86
-30.98
40.80
-8.77
Opening Cash & Equivalents
83.74
153.07
439.32
22.77
23.96
16.11
47.09
6.29
15.06
Closing Cash & Equivalent
199.07
83.74
153.08
439.32
26.83
23.96
16.11
47.09
6.29

Financial Ratios

Consolidated /

Standalone
Description
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Book Value (Rs.)
144.23
117.78
100.92
84.74
46.93
35.84
26.68
20.95
49.10
ROA
13.59%
12.70%
15.90%
35.39%
18.76%
18.79%
14.79%
13.27%
9.92%
ROE
24.00%
20.42%
23.25%
58.03%
36.24%
39.97%
36.81%
39.14%
31.62%
ROCE
22.66%
22.15%
28.87%
65.87%
37.54%
43.54%
32.05%
28.93%
21.52%
Fixed Asset Turnover
2.85
2.86
3.07
3.24
2.71
3.02
2.95
3.28
2.79
Receivable days
47.09
50.43
40.13
41.02
55.91
49.38
51.58
49.79
60.94
Inventory Days
78.91
79.67
70.01
54.91
61.11
56.34
62.73
59.30
66.15
Payable days
91.89
98.47
84.03
83.80
69.83
66.49
69.05
51.02
50.77
Cash Conversion Cycle
34.11
31.63
26.12
12.13
47.19
39.23
45.26
58.07
76.32
Total Debt/Equity
0.42
0.32
0.05
0.07
0.30
0.16
0.37
0.89
1.21
Interest Cover
41.70
160.20
102.16
173.43
95.30
30.87
9.60
5.29
4.87

Annual Reports:

FY 2019
FY 2018
FY 2017
FY 2016
FY 2015
FY 2014
FY 2013
FY 2012

News Update:


  • Alembic Pharmaceuticals’ JV receives USFDA’s approval for Clobetasol Propionate Shampoo
    19th May 2020, 11:04 AM

    Alembic has a cumulative total of 122 ANDA approvals (109 final approvals and 13 tentative approvals) from USFDA

    Read More
  • Alembic Pharmaceuticals gets USFDA’s final approval for Doxycycline Hyclate Tablets
    15th May 2020, 13:19 PM

    The company has a cumulative total of 121 ANDA approvals from USFDA

    Read More
  • Alembic Pharmaceuticals’ JV gets EIR from USFDA for formulation facility at Gujarat
    6th May 2020, 11:54 AM

    The inspection was carried out by them at Aleor's Formulation Facility at Karakhadi, Gujarat, India during the period from January 6, 2020 to January 8, 2020

    Read More
  • Alembic Pharmaceuticals’ Panelav facility gets VAI from USFDA
    4th May 2020, 11:29 AM

    Inspection at the said Facility was conducted by USFDA from March 09, 2020 to March 13, 2020

    Read More
  • Alembic Pharmaceuticals gets USFDA’s tentative approval for Alcaftadine Ophthalmic Solution
    20th Apr 2020, 10:30 AM

    Alcaftadine Ophthalmic Solution is an H1 histamine receptor antagonist indicated for the prevention of itching associated with allergic conjunctivitis

    Read More
  • Alembic Pharma receives EIR for API Facility at Karakhadi
    17th Mar 2020, 11:25 AM

    USFDA had inspected the said facility during the period from January 13, 2020 to January 17, 2020

    Read More
  • USFDA conducts inspection at Alembic Pharma’s Panelav facility
    16th Mar 2020, 09:33 AM

    This was a scheduled inspection and at the end of the inspection, the USFDA issued a Form 483 with four procedural observations

    Read More
  • Alembic Pharmaceuticals gets nod from USFDA for Doxycycline Hyclate Tablets
    5th Mar 2020, 11:38 AM

    Doxycycline Hyclate Tablets are indicated for use as an adjunct to scaling and root planing to promote attachment level gain and to reduce pocket depth in patients with adult periodontitis

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.